癌症中的胰岛素样生长因子1受体：旧焦点，新未来。

The insulin-like growth factor 1 receptor in cancer: old focus, new future.

作者信息

Hartog Hermien, Wesseling Jelle, Boezen H Marike, van der Graaf Winette T A

机构信息

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

出版信息

Eur J Cancer. 2007 Sep;43(13):1895-904. doi: 10.1016/j.ejca.2007.05.021. Epub 2007 Jul 10.

DOI:10.1016/j.ejca.2007.05.021

PMID:17624760

Abstract

The importance of insulin-like growth factor 1 receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases I and II clinical trials. Interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors.

摘要

胰岛素样生长因子1受体（IGF-1R）信号传导在肿瘤细胞恶性行为中的重要性已得到充分证实。目前，作为抗癌治疗手段，靶向IGF-1R的药物研发正在兴起。几种靶向IGF-1R的策略正在进行I期和II期临床试验。然而，IGF-1R与胰岛素受体的相互作用可能会使这类药物的疗效和耐受性变得复杂。本综述描述了IGF-1R抗体和酪氨酸激酶抑制剂的作用机制、最新进展及潜在局限性。